662 related articles for article (PubMed ID: 27366922)
21. The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW.
van der Horst-Bruinsma I; van Bentum R; Verbraak FD; Rath T; Rosenbaum JT; Misterska-Skora M; Hoepken B; Irvin-Sellers O; VanLunen B; Bauer L; Rudwaleit M
RMD Open; 2020 Apr; 6(1):. PubMed ID: 32371433
[TBL] [Abstract][Full Text] [Related]
22. Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials.
Curtis JR; Mariette X; Gaujoux-Viala C; Blauvelt A; Kvien TK; Sandborn WJ; Winthrop K; de Longueville M; Huybrechts I; Bykerk VP
RMD Open; 2019; 5(1):e000942. PubMed ID: 31245056
[TBL] [Abstract][Full Text] [Related]
23. The term 'non-radiographic axial spondyloarthritis' is much more important to classify than to diagnose patients with axial spondyloarthritis.
Deodhar A; Strand V; Kay J; Braun J
Ann Rheum Dis; 2016 May; 75(5):791-4. PubMed ID: 26768406
[TBL] [Abstract][Full Text] [Related]
24. Comparison of patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) from a single rheumatology clinic in New Delhi.
Malaviya AN; Kalyani A; Rawat R; Gogia SB
Int J Rheum Dis; 2015 Sep; 18(7):736-41. PubMed ID: 26172961
[TBL] [Abstract][Full Text] [Related]
25. Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis.
Braun J; Baraliakos X; Hermann KG; Landewé R; Machado PM; Maksymowych WP; Davies O; Hoepken B; Nurminen T; Stach C; van der Heijde D
RMD Open; 2017; 3(1):e000430. PubMed ID: 28848654
[TBL] [Abstract][Full Text] [Related]
26. Certolizumab Pegol Efficacy in Patients With Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status: An Analysis From the C-axSpAnd Study.
Robinson PC; Maksymowych WP; Gensler LS; Hall S; Rudwaleit M; Hoepken B; Bauer L; Kumke T; Kim M; de Peyrecave N; Deodhar A
ACR Open Rheumatol; 2022 Sep; 4(9):794-801. PubMed ID: 35733363
[TBL] [Abstract][Full Text] [Related]
27. Tumour necrosis factor-α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation.
Corbett M; Soares M; Jhuti G; Rice S; Spackman E; Sideris E; Moe-Byrne T; Fox D; Marzo-Ortega H; Kay L; Woolacott N; Palmer S
Health Technol Assess; 2016 Feb; 20(9):1-334, v-vi. PubMed ID: 26847392
[TBL] [Abstract][Full Text] [Related]
28. Pharmacological management of axial spondyloarthritis in adults.
Toussirot E
Expert Opin Pharmacother; 2019 Aug; 20(12):1483-1491. PubMed ID: 31095430
[No Abstract] [Full Text] [Related]
29. Ixekizumab for treating ankylosing spondylitis.
Kiwalkar S; Beier S; Deodhar A
Immunotherapy; 2019 Oct; 11(15):1273-1282. PubMed ID: 31530049
[TBL] [Abstract][Full Text] [Related]
30. Certolizumab pegol in axial spondyloarthritis.
Song IH; Rudwaleit M
Expert Rev Clin Immunol; 2013 Dec; 9(12):1161-72. PubMed ID: 24215406
[TBL] [Abstract][Full Text] [Related]
31. Risk of serious infections in biological treatment of patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.
Wang S; He Q; Shuai Z
Clin Rheumatol; 2018 Feb; 37(2):439-450. PubMed ID: 29290076
[TBL] [Abstract][Full Text] [Related]
32. Advances in pharmacotherapies for axial spondyloarthritis.
Toussirot E
Expert Opin Pharmacother; 2023; 24(13):1439-1448. PubMed ID: 37318776
[TBL] [Abstract][Full Text] [Related]
33. Certolizumab pegol treatment in axial spondyloarthritis mitigates fat lesion development: 4-year post-hoc MRI results from a phase 3 study.
Baraliakos X; Kruse S; Auteri SE; de Peyrecave N; Nurminen T; Kumke T; Hoepken B; Braun J
Rheumatology (Oxford); 2022 Jul; 61(7):2875-2885. PubMed ID: 34791107
[TBL] [Abstract][Full Text] [Related]
34. Tumor necrosis factor alpha antagonists in the treatment of axial spondyloarthritis.
Braun J; Baraliakos X; Heldmann F; Kiltz U
Expert Opin Investig Drugs; 2014 May; 23(5):647-59. PubMed ID: 24654630
[TBL] [Abstract][Full Text] [Related]
35. Radiographic progression in non-radiographic axial spondyloarthritis.
Protopopov M; Poddubnyy D
Expert Rev Clin Immunol; 2018 Jun; 14(6):525-533. PubMed ID: 29774755
[TBL] [Abstract][Full Text] [Related]
36. Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study.
Gehin JE; Goll GL; Warren DJ; Syversen SW; Sexton J; Strand EK; Kvien TK; Bolstad N; Lie E
Arthritis Res Ther; 2019 Nov; 21(1):256. PubMed ID: 31783773
[TBL] [Abstract][Full Text] [Related]
37. Impact of Certolizumab Pegol on Patient-Reported Outcomes in Patients With Axial Spondyloarthritis.
Sieper J; Kivitz A; van Tubergen A; Deodhar A; Coteur G; Woltering F; Landewé R
Arthritis Care Res (Hoboken); 2015 Oct; 67(10):1475-80. PubMed ID: 25832312
[TBL] [Abstract][Full Text] [Related]
38. Comparing symptoms, treatment patterns, and quality of life of ankylosing spondylitis and non-radiographic axial spondyloarthritis patients in the USA: findings from a patient and rheumatologist Survey.
Hunter T; Sandoval D; Booth N; Holdsworth E; Deodhar A
Clin Rheumatol; 2021 Aug; 40(8):3161-3167. PubMed ID: 33611647
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness and Safety of Certolizumab Pegol in Axial Spondyloarthritis in a Real-World Setting in Greece: A Sub-Analysis of the Prospective Non-Interventional CIMAX Cohort Study.
Katsifis G; Theodoridou A; Bounas A; Georgiou P; Sfikakis P; Fragiadaki K; Dimitroulas T; Mole E; Bauer L; Kumke T; Hoepken B
Mediterr J Rheumatol; 2022 Mar; 33(Suppl 1):162-172. PubMed ID: 36127922
[TBL] [Abstract][Full Text] [Related]
40. Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritis.
Ciurea A; Scherer A; Weber U; Exer P; Bernhard J; Tamborrini G; Riek M; Müller RB; Weiss B; Nissen MJ; Kissling R; Michel BA; Finckh A;
Ann Rheum Dis; 2016 Mar; 75(3):532-9. PubMed ID: 25667205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
